8:20 am Chair’s Opening Remarks: The Value Proposition of Early Identification & Intervention of Kidney Disease

SGLT2: What’s Next? Highlighting Challenge & Opportunity for Additional Drug Development

8:45 am Learning from Diabetes & Heart Failure Conversations: Drug Development in Addition to SGLT2 Inhibition as Standard of Care

  • Jyothis George Global Head of Diabetes Clinical Development, Boehringer Ingelheim

9:15 am Panel Discussion: Demonstrating Opportunity in Renal to Support a Business Case:

  • Jyothis George Global Head of Diabetes Clinical Development, Boehringer Ingelheim
  • Uptal Patel Executive Director, Clinical Research, Gilead
  • Romer Gonzalez-Villalobos Associate Director CKD/ NASH, Cardiovascular & Metabolism, Janssen Pharmaceuticals

9:45 am Speed Networking

10:30 am Morning Break & Networking

Translational Drug Development Track

Chaired By: Jeremy Duffield, Global Head of Human Biology, Vertex Pharmaceuticals

Later Stage Clinical& Commercial Drug Development Track

Chaired By: Uptal Patel, Executive Director, Clinical Research, Gilead

Disease Modeling for More Predictive Translation & Mechanistic Discovery 

11.30 Applications of Kidney Organoid Disease Models to Optimize Drug Discovery Opportunity 

Beno Freedman, Assistant Professor – Nephrology, University of Washington

 

12.00 Bioengineering Technologies to Model Renal Systems

Jonathan Himmelfarb, Director of the Kidney Research Institute & Professor of Medicine, University of Washington

 

Accessing & Interrogating Data to Inform Drug Target Discovery

 

12.30 Tissue Transcriptomics to Understand Molecular Mechanisms of Progressive CKD & Mechanism-based Patient Stratification

Wenjun Ju, Associate Research Scientist of Internal Medicine, University of Michigan

 

Enhancing Patient Recruitment & Selection for Clinical Trials in Orphan Indications

11.30 Biomarkers as Key Drug Development Tools 

Vishal Vaidya, Translational Omics Group Head, Pfizer

 

12.00 From Diagnostic to Therapeutic Targets

Tzu-Ling (Karen) Tseng, Chief Executive Officer, Bio Preventive Medicine Corp

 

12.30 Panel Discussion: Advantages & Disadvantages of Targeting Trials to Specific Orphan Indications Versus Larger Public Health Problems

Dorothee Oberdhan, Associate Director, Health Outcomes, Otsuka Pharmaceuticals

Josh Tarnoff, Chief Executive Officer, NephCure

Uptal Patel, Executive Director, Clinical Research, Gilead

1:00 pm Lunch & Networking

2:00 pm Rationale & Results of Subgroup Analyses of the CREDENCE Study

  • Yshai Yavin Director, Cardiovascular & Metabolism Development , Janssen Pharmaceuticals

Implementing Precision Medicine in Renal Disease Studying Genetic Drivers & Targetable Mutations in Chronic Kidney Disease

2:30 pm Pathway Driven Patient Stratification in Glomerular Disease: A Report From the Trenches

  • Matthias Kretzler Professor of Medicine Nephrology/ Internal Medicine & Bioinformatics, University of Michigan

3:00 pm APOL1 – A Genetic Driver of Kidney Disease: From Concept to Clinical Trials

3:30 pm Afternoon Break & Networking

4:00 pm Targeting FSGS as an Entry Point in CKD: Expanding From a Smaller Market

  • Liron Walsh Vice President of Translational & Clinical Nephrology, Goldfinch Bio

4:30 pm Panel Discussion: Executing Precision Medicine in Clinical Trials

  • Andrew King Head of Renal Discovery & Translational Medicine, Chinook Therapeutics
  • Matthias Kretzler Professor of Medicine Nephrology/ Internal Medicine & Bioinformatics, University of Michigan
  • Liron Walsh Vice President of Translational & Clinical Nephrology, Goldfinch Bio
  • Heather Ascani Director, Business Operations & Applied Systems Biology, University of Michigan
  • Jeremy Duffield Global Head of Human Biology, Vertex Pharmaceuticals

5:00 pm Chair’s Closing Remarks

5:15 pm Poster Session